Loading organizations...
Based in London, DaltonTx develops an adaptive artificial intelligence platform designed to integrate into pharmaceutical workflows and power drug discovery for both small molecules and biologics. The company provides a reasoning engine that learns from experiments, computational models, and scientists to continuously improve research and development outcomes for biotechnology firms and contract research organizations. In September 2025, the enterprise exited stealth mode and announced a £4 million seed funding round to expand its engineering team in the King's Cross area and accelerate new industry partnerships. This initial financing was supported by a syndicate of prominent venture capital firms, specifically including investors redalpine, IQ Capital Partners, and Seedcamp. While the company's exact founding year remains undisclosed, the startup was established by co-founders Dr Garry Pairaudeau, Adrian Rossall, Dr Anthony Bradley, and Professor Charlotte Deane MBE.
DaltonTx has raised $5.0M across 1 funding round.
DaltonTx has raised $5.0M in total across 1 funding round.
DaltonTx is a UK-based technology company developing an adaptive, AI-enabled platform designed to transform drug discovery. Their platform integrates machine learning with deep domain expertise to support pharmaceutical, biotech, and contract research organizations (CROs) throughout the entire drug discovery process—from data ingestion and model training to molecule design and experiment prioritization. It serves scientists by embedding directly into their workflows, enabling collaborative intelligence where human expertise and AI work together to accelerate and improve R&D outcomes. The platform supports both small molecules and biologics, addressing complex therapeutic pipelines and aiming to reduce timelines, costs, and risks in drug development[1][2][3][4][5].
DaltonTx was co-founded in 2025 by Dr. Garry Pairaudeau, Adrian Rossall, Dr. Anthony Bradley, and Professor Charlotte Deane MBE, who bring extensive backgrounds in drug discovery, machine learning, and software engineering. The founders have experience at AstraZeneca, Exscientia, and the University of Oxford, blending academic research with industry expertise. The idea emerged from recognizing the inefficiencies and high costs in traditional drug discovery and the limitations of existing AI platforms that focus on building proprietary drug pipelines rather than enabling pharma at scale. Early traction included securing £4 million in seed funding led by Redalpine, with participation from IQ Capital Partners, Seedcamp, and Oxford University Innovation, validating the vision of creating an intelligence backbone for modern R&D[1][2][3][4].
DaltonTx is positioned at the intersection of AI, engineering, and life sciences, riding the trend of integrating advanced machine learning into pharmaceutical R&D to overcome traditional bottlenecks. The timing is critical as the drug discovery industry faces pressure to reduce costs and accelerate timelines while managing increasing complexity in therapeutic targets. DaltonTx’s approach addresses market demands for adaptive, scalable AI infrastructure that supports collaborative workflows rather than replacing scientists. By providing an intelligence backbone that learns and evolves, DaltonTx influences the broader ecosystem by enabling more efficient innovation, potentially reshaping how medicines are discovered and delivered globally[1][2][3][4].
DaltonTx is poised to become a foundational technology provider in drug discovery, with its adaptive AI platform likely to gain widespread adoption across pharma, biotech, and CROs. Future trends shaping their journey include increasing reliance on AI for complex biologics, demand for integrated digital workflows, and the push for faster, more cost-effective R&D. As the platform matures, DaltonTx’s influence may expand beyond discovery into broader areas of pharmaceutical development, solidifying its role as the intelligence backbone that accelerates breakthrough therapies. Their continued growth will depend on successful integration with industry partners and demonstrating measurable improvements in drug discovery efficiency and outcomes[1][2][3][4].
DaltonTx has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2025 | $5M Seed | — | Mkt1 Capital, Seedcamp, Mason Sinclair, Marc Moesser | Announced |
DaltonTx has raised $5.0M in total across 1 funding round.
DaltonTx's investors include MKT1 Capital, Seedcamp, Mason Sinclair, Marc Moesser.
